SUNDAY, MARCH 5
Arrival and Registration

MONDAY, MARCH 6
Welcome and Keynote Address
James P. Allison, University of Texas MD Anderson Cancer Center, USA
Checkpoint Blockade: Where do we go from Here?

Dysfunctional Immune Cells in the TME
Patrick G. Hogan, La Jolla Institute of Allergy and Immunology, USA
Transcriptional Mechanisms of CD8 TIL Dysfunction
Barbara Maier, Austrian Academy of Sciences, Austria
Regulatory DCs
Evan W. Newell, Fred Hutchinson Cancer Research Center, USA
Understanding TIL Dysfunction using scRNAseq
Short Talks Chosen from Abstracts

Innate Immune Cells in the Cancer Context
Marco Colonna, Washington University School of Medicine, USA
TREM2 and Macrophages
Speaker to be Announced
Stefani Spranger, Massachusetts Institute of Technology, USA
Dendritic Cells in Anti-Tumor Immunity
Short Talks Chosen from Abstracts

Post Session 1

TUESDAY, MARCH 7
Vaccines
Speaker to be Announced
Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, USA
Properties of Tumor Neoantigens Determining Induction of Immunity
Catherine J. Wu, Dana-Farber Cancer Institute, USA
Neoepitope Vaccines
Robert D. Schreiber, Washington University School of Medicine, USA
Integrating CD4 and CD8 Epitopes
Short Talks Chosen from Abstracts

Tumor Microenvironment
Janis Taube, Johns Hopkins University, USA
In situ Imaging of the Tumor Microenvironment
Fatima Mehta-Grigorou, Curie Research Institute, France
scRNAseq of Intratumoral Fibroblasts
Raphael Gottardo, Fred Hutchinson Cancer Research Center, USA
In situ Transcriptomics
Short Talks Chosen from Abstracts

Poster Session 2

WEDNESDAY, MARCH 8
Learning from the Patient: Reverse Translation
Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
Checkpoint Blockade Mechanisms of Response versus Resistance
Justin Kline, University of Chicago, USA
Immunotherapy Efficacy versus Resistance in NHL
Speaker to be Announced
Christian U. Blank, Netherlands Cancer Institute - NKI-AVL, Netherlands
Biomarkers of Response to Neoadjuvant Checkpoint Blockade
Short Talks Chosen from Abstracts

Innate Immune Pathways and the Anti-Tumor Response
Carla V. Rothlin, Yale University, USA
MerTK Family in Anti-Tumor Immunity
Michael Karin, University of California, San Diego, USA
Inflammation and Cancer: A Double Edged Sword
Brian Ruffell, H. Lee Moffitt Cancer Center & Research Institute, USA
TIM-3 and the STING Pathway in Dendritic Cells
Short Talks Chosen from Abstracts

Poster Session 3

THURSDAY, MARCH 9
Host Factors Impacting Immunotherapy Efficacy
Thomas Gajewski, University of Chicago, USA
Germline Variants Regulating Anti-Tumor Immunity
Laurence Zitvogel, Institut Gustave Roussy, France
Gut Immune Checkpoint in Cancer Immunotherapy
Speaker to be Announced
Speaker to be Announced
Short Talks Chosen from Abstracts

Engineered Immune Cell Strategies
Philip D. Greenberg, University of Washington, USA
Engineered T Cell Therapies for Solid Tumors
Andrew M. Scharenberg, Umoja Biopharma, USA
Novel T Cell Engineering Strategies
Katy Rezvani, University of Texas MD Anderson Cancer Center, USA
CAR-NK Cells
Marcela V. Maus, Harvard Medical School, USA
Mechanisms Driving CAR T Cells
Short Talks Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, MARCH 10
* Session Chair † Invited but not yet accepted Program current as of November 17, 2022 Meal formats are based on meeting venue. For the most up-to-date details, visit https://www.keystonesymposia.org.
Departure